Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Next Cox-2 Battle: Merck, Novartis Drugs Face Vocal Resistance

This article was originally published in RPM Report

Executive Summary

Novartis AG and Merck & Co. Inc. beware: Steven Nissen doesn't want your investigational cox-2 inhibitors to win approval from the Food & Drug Administration.

You may also be interested in...



Inside the Mind of a Serial Drug Killer

The Cleveland Clinic's Steve Nissen has taken it upon himself to lead a drug safety crusade on behalf of patients that has ruined some high-profile drugs, elevated his status in the scientific world and captivated the drug industry. Why is he doing it-and will he continue?

Inside the Mind of a Serial Drug Killer

The Cleveland Clinic's Steve Nissen has taken it upon himself to lead a drug safety crusade on behalf of patients that has ruined some high-profile drugs, elevated his status in the scientific world and captivated the drug industry. Why is he doing it-and will he continue?

The Death of Arcoxia: Drug Regulation in a "Whistleblower" Climate

There may not be a worse time to push a new drug through FDA-especially a "me-too" product with a questionable benefit-risk profile. Until Congress releases its grasp on the approval process, FDA isn't taking any chances. Unfortunately for industry, a few drugs are getting caught in the crossfire. Merck seemed unprepared for the new climate with Arcoxia; will other sponsors learn the lesson?

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS080177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel